Hojoon Sohn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/400756/publications.pdf

Version: 2024-02-01

33 papers	1,539 citations	535685 17 h-index	511568 30 g-index
33 all docs	33 docs citations	33 times ranked	2145 citing authors

#	Article	IF	Citations
1	Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ Global Health, 2022, 7, e007182.	2.0	13
2	Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda. Value in Health, 2022, 25, 924-930.	0.1	8
3	A cost analysis of implementing mobile health facilitated tuberculosis contact investigation in a low-income setting. PLoS ONE, 2022, 17, e0265033.	1.1	6
4	Evaluating the impact of the nationwide publicâ€“private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: A difference in differences analysis. PLoS Medicine, 2021, 18, e1003717.	3.9	14
5	Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia. PLoS ONE, 2021, 16, e0256531.	1.1	13
6	Metaâ€analysis of the difference of medians. Biometrical Journal, 2020, 62, 69-98.	0.6	92
7	Costing the implementation of public health interventions in resource-limited settings: a conceptual framework. Implementation Science, 2020, 15, 86.	2.5	43
8	Redefining and revisiting cost estimates of routine ART care in Zambia: an analysis of ten clinics. Journal of the International AIDS Society, 2020, 23, e25431.	1.2	6
9	Standardized framework for evaluating costs of active case-finding programs: An analysis of two programs in Cambodia and Tajikistan. PLoS ONE, 2020, 15, e0228216.	1.1	15
10	Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). Implementation Science, 2020, 15, 24.	2.5	14
11	Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model. BMC Medicine, 2019, 17, 155.	2.3	19
12	Cost and operational impact of promoting upfront GeneXpert MTB/RIF test referrals for presumptive pediatric tuberculosis patients in India. PLoS ONE, 2019, 14, e0214675.	1.1	11
13	Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation. The Lancet Global Health, 2019, 7, e798-e807.	2.9	33
14	Operational characteristics of antiretroviral therapy clinics in Zambia: a time and motion analysis. BMC Health Services Research, 2019, 19, 244.	0.9	11
15	Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Clinical Infectious Diseases, 2018, 67, 1072-1078.	2.9	43
16	Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: A trend analysis from 2014 - 2016. Gates Open Research, 2018, 2, 35.	2.0	54
17	Exploring the epidemiological impact of universal access to rapid tuberculosis diagnosis using agent-based simulation. , 2017, , .		2
18	Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies. PLoS ONE, 2016, 11, e0151073.	1.1	37

#	Article	IF	Citations
19	The Sensitivity and Specificity of Loop-Mediated Isothermal Amplification (LAMP) Assay for Tuberculosis Diagnosis in Adults with Chronic Cough in Malawi. PLoS ONE, 2016, 11, e0155101.	1.1	42
20	The Feasibility, Accuracy, and Impact of Xpert MTB/RIF Testing in a Remote Aboriginal Community in Canada. Chest, 2015, 148, 767-773.	0.4	10
21	Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study. BMC Infectious Diseases, 2015, 15, 253.	1.3	49
22	Xpert MTB/RIF Testing in a Low Tuberculosis Incidence, High-Resource Setting: Limitations in Accuracy and Clinical Impact. Clinical Infectious Diseases, 2014, 58, 970-976.	2.9	87
23	XpertÂ® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. , 2013, , CD009593.		283
24	Multicentre evaluation of Ziehl-Neelsen and light-emitting diode fluorescence microscopy in China. International Journal of Tuberculosis and Lung Disease, 2013, 17, 107-112.	0.6	44
25	Cost-Effectiveness Comparison of Genechip and Conventional Drug Susceptibility Test for Detecting Multidrug-Resistant Tuberculosis in China. PLoS ONE, 2013, 8, e69267.	1.1	12
26	Comparative cost and performance of light-emitting diode microscopy in HIVâ€“tuberculosis-co-infected patients. European Respiratory Journal, 2011, 38, 1393-1397.	3.1	27
27	Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. PLoS Medicine, 2011, 8, e1001120.	3.9	264
28	An Integrated Approach to Rapid Diagnosis of Tuberculosis and Multidrug Resistance Using Liquid Culture and Molecular Methods in Russia. PLoS ONE, 2009, 4, e7129.	1.1	52
29	Light-emitting diode technologies for TB diagnosis: what is on the market?. Expert Review of Medical Devices, 2009, 6, 341-345.	1.4	41
30	Diagnostic performance and costs of Capilia TB for Mycobacterium tuberculosis complex identification from brothâ€based culture in Bangkok, Thailand. Tropical Medicine and International Health, 2009, 14, 748-753.	1.0	45
31	Novel and Improved Technologies for Tuberculosis Diagnosis: Progress and Challenges. Clinics in Chest Medicine, 2009, 30, 701-716.	0.8	118
32	TB diagnostic tests: how do we figure out their costs?. Expert Review of Anti-Infective Therapy, 2009, 7, 723-733.	2.0	29
33	Cost and affordability analysis of TB-LAMP and Xpert MTB/RIF assays as routine diagnostic tests in peripheral laboratories in Malawi and Vietnam. Journal of Global Health Science, 0, 1, .	1.7	2